Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > ARCHIVE
ARCHIVE
- Astellas Looking for Partner for Global Development of Darexaban
June 6, 2011
- ASKA's Emergency Pill Priced at ¥10,000/Dose
June 6, 2011
- Teijin Pharma to Collect More Evidence on Efficacy of Feburic for Hyperuricemia
June 6, 2011
- JPA Opposes Drug Price Revision without Revision of Medical, Nursing Fees
June 6, 2011
- Santen Regains Top Spot in Domestic Glaucoma Market
June 6, 2011
- Sitagliptin Approved for Combination Therapy with αGI: MSD, Ono
June 6, 2011
- Seikagaku Preparing to Launch Gel-One in US Despite Patent Dispute
June 6, 2011
- Pfizer Files Simultaneous Application for Crizotinib in the US, Japan
June 6, 2011
- Teva to Acquire Majority Stake in Taiyo
May 30, 2011
- Premium for New Drug Development an “Incentive”to Japan Business: Chairman Viehbacher of PhRMA
May 30, 2011
- Teva-Taiyo Strategic Tie-up to Have “No Major Impact”on Sawai: President Sawai
May 30, 2011
- Astellas Completes Acquisition of Perseid
May 30, 2011
- Korosho Approves 2 Class 1 OTC Anti-allergic Eye Drops
May 30, 2011
- Daiichi Sankyo Launches SPRIX Nasal Spray in US
May 30, 2011
- Sanofi-aventis Changes Corporate Name to Sanofi
May 30, 2011
- NanoCarrier's NC-4016 to Obtain Substance Patent in US
May 30, 2011
- Takeda to Acquire Nycomed for 9.6 Bil. Euros
May 30, 2011
- JMA Formally Requests Postponement of Medical, Nursing Fee Revisions
May 30, 2011
- Top-10 Domestic Drug Makers' Sales, Profits Down due to Patent Expirations
May 30, 2011
- “Strict Warning”Issued to MSD for 4 Violations of Fair Promotion Code
May 30, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…